Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Alkaloids Indolizidine 235B′, Quinolizidine 1-epi-207I, and the Tricyclic 205B are Potent and Selective Noncompetitive Inhibitors of Nicotinic Acetylcholine Receptors

Hiroshi Tsuneki, Yueren You, Naoki Toyooka, Syota Kagawa, Soushi Kobayashi, Toshiyasu Sasaoka, Hideo Nemoto, Ikuko Kimura and John A. Dani
Molecular Pharmacology October 2004, 66 (4) 1061-1069; DOI: https://doi.org/10.1124/mol.104.000729
Hiroshi Tsuneki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yueren You
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Naoki Toyooka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Syota Kagawa
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Soushi Kobayashi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Toshiyasu Sasaoka
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hideo Nemoto
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ikuko Kimura
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John A. Dani
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

Nicotinic acetylcholine receptors are key molecules in cholinergic transmission in the nervous system. Because of their structural complexity, only a limited number of subtype-specific agonists and antagonists are available to study nicotinic receptor functions. To overcome this limitation, we used voltageclamp recordings to examine the effects of several frog skin alkaloids on acetylcholine-elicited currents in Xenopus laevis oocytes expressing major types of neuronal nicotinic receptors (α4β2, α7, α3β2, α3β4, and α4β4). We found that the 5,8-disubstituted indolizidine (-)-235B′ acted as a potent noncompetitive blocker of α4β2 nicotinic receptors (IC50 = 74 nM). This effect was highly selective for α4β2 receptors compared with α3β2, α3β4, and α4β4 receptors. The inhibition of α4β2 currents by (-)-235B′ was more pronounced as the acetylcholine concentration increased (from 10 nM to 100 μM). Moreover, the blockade of α4β2 currents by (-)-235B′ was voltage-dependent (more pronounced at hyperpolarized potentials) and use-dependent, indicating that (-)-235B′ behaves as an open-channel blocker of this receptor. Several other 5,8-disubstituted indolizidines (5-n-propyl-8-n-butylindolizidines), two 5,6,8-trisubstituted indolizidines ((-)-223A and (+)-6-epi-223A), and a 1,4-disubstituted quinolizidine ((+)-207I) were less potent than (-)-235B′, and none showed selectivity for α4β2 receptors. The quinolizidine (-)-1-epi-207I and the tricyclic (+)-205B had 8.7- and 5.4-fold higher sensitivity, respectively, for inhibition of the α7 nicotinic receptor than for inhibition of the α4β2 receptor. These results show that frog alkaloids alter the function of nicotinic receptors in a subtype-selective manner, suggesting that an analysis of these alkaloids may aid in the development of selective drugs to alter nicotinic cholinergic functions.

  • Received March 25, 2004.
  • Accepted July 6, 2004.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 66 (4)
Molecular Pharmacology
Vol. 66, Issue 4
1 Oct 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Alkaloids Indolizidine 235B′, Quinolizidine 1-epi-207I, and the Tricyclic 205B are Potent and Selective Noncompetitive Inhibitors of Nicotinic Acetylcholine Receptors
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Alkaloids Indolizidine 235B′, Quinolizidine 1-epi-207I, and the Tricyclic 205B are Potent and Selective Noncompetitive Inhibitors of Nicotinic Acetylcholine Receptors

Hiroshi Tsuneki, Yueren You, Naoki Toyooka, Syota Kagawa, Soushi Kobayashi, Toshiyasu Sasaoka, Hideo Nemoto, Ikuko Kimura and John A. Dani
Molecular Pharmacology October 1, 2004, 66 (4) 1061-1069; DOI: https://doi.org/10.1124/mol.104.000729

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

Alkaloids Indolizidine 235B′, Quinolizidine 1-epi-207I, and the Tricyclic 205B are Potent and Selective Noncompetitive Inhibitors of Nicotinic Acetylcholine Receptors

Hiroshi Tsuneki, Yueren You, Naoki Toyooka, Syota Kagawa, Soushi Kobayashi, Toshiyasu Sasaoka, Hideo Nemoto, Ikuko Kimura and John A. Dani
Molecular Pharmacology October 1, 2004, 66 (4) 1061-1069; DOI: https://doi.org/10.1124/mol.104.000729
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • The binding site for KCI807 in the androgen receptor
  • Fatty acid amide hydrolase in cisplatin nephrotoxicity
  • eCB Signaling System in hiPSC-Derived Neuronal Cultures
Show more Article

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics